Hindustan Laboratories, a key player in the Indian pharmaceutical sector, has received observations from the Securities and Exchange Board of India (Sebi) for its initial public offering (IPO). The proposed IPO will consist of up to 14.1 million equity shares with a face value of ₹10 each. This includes a fresh issue of 5 million shares and an offer for sale (OFS) of 9.1 million shares by existing shareholders. The company plans to use the net proceeds primarily to fund its working capital needs and for general corporate purposes. Hindustan Laboratories specializes in the production of generic pharmaceuticals, focusing on affordable medicines whose patents have expired, thus making them accessible to a broader population. The company operates mainly through business-to-government (B2G) models, supplying medicines to government projects via the Ministry of Health and Family Welfare and various state bodies. Additionally, RK Steel Manufacturing has also received Sebi's nod for its IPO, further diversifying the offerings in the market. Founded in 2006, RK Steel is known for manufacturing welded structural steel tubes and pipes, including a range of products from Pre-Galvanised Pipes to value-added items like GP Coils.